nach oben

Wiener Medizinische Wochenschrift

Erschienen in:

01.07.2012 | Kalzium in der kardialen Pathophysiologie

Calcium antagonists in myocardial ischemia/reperfusion—update 2012

verfasst von: Petra Kleinbongard, PhD, Theodor Baars, MD, Prof. Dr. med. Dr. h.c. Gerd Heusch, FRCP

Erschienen in: Wiener Medizinische Wochenschrift | Ausgabe 13-14/2012

Einloggen, um Zugang zu erhalten

Summary

The present article briefly reviews the processes underlying excitation–contraction coupling in cardiomyocytes and vascular smooth muscle cells, their perturbations during reversible and irreversible myocardial ischemia and reperfusion, notably the pathogenetic role of increased intracellular calcium concentrations, and finally the beneficial effects of calcium antagonists on the impairment of coronary vasomotor tone, on cardiac contractile dysfunction and on myocardial infarction.

Vorheriger Artikel Calcium handling in human heart failure—abnormalities and target for therapy

Nächster Artikel Pharmacology of myocardial calcium-handling

Bers DM. Calcium cycling and signaling in cardiac myocytes. Annu Rev Physiol. 2008;70:23–49.PubMedCrossRef

Ramirez RJ, Sah R, Liu J, Rose RA, Backx PH. Intracellular [Na⁺] modulates synergy between Na⁺/Ca²⁺ exchanger and L-type Ca²⁺ current in cardiac excitation-contraction coupling during action potentials. Basic Res Cardiol. 2011;106:967–77.PubMedCrossRef

Berridge MJ. Smooth muscle cell calcium activation mechanisms. J Physiol. 2008;586:5047–61.PubMedCrossRef

House SJ, Potier M, Bisaillon J, Singer HA, Trebak M. The non-excitable smooth muscle: calcium signaling and phenotypic switching during vascular disease. Pflügers Arch. 2008;456:769–85.PubMedCrossRef

Ono K, Iijima T. Cardiac T-type Ca²⁺ channels in the heart. J Mol Cell Cardiol. 2010;48:65–70.PubMedCrossRef

Fabritz L, Herzig S. Can T-type calcium channels make a change of heart after myocardial infarction? Fiction or fact, and for better or for worse? Cardiovasc Res. 2011;91:373–5.PubMedCrossRef

Wang SQ, Song LS, Xu L, Meissner G, Lakatta EG, Rios E, et al. Thermodynamically irreversible gating of ryanodine receptors in situ revealed by stereotyped duration of release in Ca²⁺ sparks. Biophys J. 2002;83:242–51.PubMedCrossRef

Karmazyn M, Gan XT, Humphreys RA, Yoshida H, Kusumoto K. The myocardial Na⁺-H⁺ exchange. Structure, regulation, and its role in heart disease. Circ Res. 1999;85:777–86.PubMedCrossRef

Inserte J, Garcia-Dorado A, Ruiz-Meana M, Padilla F, Barrabés JA, Pina P, et al. Effect of inhibition of Na⁺/Ca²⁺ exchanger at the time of myocardial reperfusion on hypercontracture and cell death. Cardiovasc Res. 2002;55:739–48.PubMedCrossRef

10.

Leineweber K, Heusch G, Schulz R. Regulation and role of the presynaptic and myocardial Na⁺/H⁺ exchanger NHE1: effects on the sympathetic nervous system in heart failure. Cardiovasc Drug Rev. 2007;25:123–31.PubMedCrossRef

11.

Abdallah Y, Kasseckert SA, Iraqi W, Said M, Shahzad T, Erdogan A, et al. Interplay between Ca²⁺ cycling and mitochondrial permeability transition pores promotes reperfusion-induced injury of cardiac myocytes. J Cell Mol Med. 2011;15:2478–85.PubMedCrossRef

12.

Ruiz-Meana M, Abellan A, Miro-Casas E, Garcia-Dorado D. Opening of mitochondrial permeability transition pore induces hypercontracture in Ca²⁺ overloaded cardiac myocytes. Basic Res Cardiol. 2007;102:542–52.PubMedCrossRef

13.

Heusch G, Boengler K, Schulz R. Inhibition of mitochondrial permeability transition pore opening: the holy grail of cardioprotection. Basic Res Cardiol. 2010;105:151–4.PubMedCrossRef

14.

Orrenius S, Zhivotovsky B, Nicotera P. Regulation of cell death: the calcium-apoptosis link. Nat Rev Mol Cell Biol. 2003;4:552–65.PubMedCrossRef

15.

Bolli R, Marban E. Molecular and cellular mechanisms of myocardial stunning. Physiol Rev. 1999;70:609–34.

16.

Schäfer C, Ladilov Y, Inserte J, Schäfer M, Haffner S, Garcia-Dorado D, et al. Role of the reverse mode of the Na⁺/Ca²⁺ exchanger in reoxygenation-induced cardiomyocyte injury. Cardiovasc Res. 2001;51:241–50.PubMedCrossRef

17.

Piper HM, Meuter K, Schäfer C. Cellular mechanisms of ischemia-reperfusion injury. Ann Thorac Surg. 2003;75:S644–8.PubMedCrossRef

18.

Bassenge E, Heusch G. Endothelial and neuro-humoral control of coronary blood flow in health and disease. Rev Physiol Biochem Pharmacol. 1990;116:77–165.PubMed

19.

Ferrari R. Major differences among the three classes of calcium antagonists. Eur Heart J. 1997;18(Suppl A):A56–70.PubMedCrossRef

20.

Hermsmeyer K. Role of T channels in cardiovascular function. Cardiology. 1998;89(Suppl 1):2–9.PubMedCrossRef

21.

Deussen A, Ohanyan V, Jannasch A, Yin L, Chilian W. Mechanisms of metabolic coronary flow regulation. J Mol Cell Cardiol. 2011;52:794–801.PubMedCrossRef

22.

van de Hoef TP, Nolte F, Rolandi MC, Piek JJ, van den Wijngaard JP, Spaan JA, et al. Coronary pressure-flow relations as basis for the understanding of coronary physiology. J Mol Cell Cardiol. 2011;52:786–93.PubMedCrossRef

23.

Dole WP. Autoregulation of the coronary circulation. Prog Cardiovasc Dis. 1987;29:293–323.PubMedCrossRef

24.

Canty JM Jr, Suzuki G. Myocardial perfusion and contraction in acute ischemia and chronic ischemic heart disease. J Mol Cell Cardiol. 2011;52:822–31.PubMedCrossRef

25.

Zhang C, Rogers P, Merkus D, Muller-Delp JM, Tiefenbacher CP, Potter B. Regulation of coronary microvascular resistance in health and disease. Compr Physiol. 2011;521–49 (American Physiological Society).

26.

Duncker DJ, Bache RJ, Merkus D. Regulation of coronary resistance vessel tone in response to exercise. J Mol Cell Cardiol. 2011;52:802–13.PubMedCrossRef

27.

Duncker DJ, van Zon NS, Pavek TJ, Herrlinger SK, Bache RJ. Endogenous adenosine mediates coronary vasodilatation during exercise after K⁺ ATP channel blockade. J Clin Invest. 1995;95:285–95.PubMedCrossRef

28.

Duncker DJ, van Zon NS, Ishibashi Y, et al. Role of K⁺ ATP channels and adenosine in the regulation of coronary blood flow during exercise with normal and restricted coronary blood flow. J Clin Invest. 1996;97:996–1009.PubMedCrossRef

29.

Ishibashi Y, Duncker DJ, Zhang J, et al. ATP-sensitive K⁺ channels, adenosine, and nitric oxide-mediated mechanisms account for coronary vasodilation during exercise. Circ Res. 1998;82:346–59.PubMedCrossRef

30.

Liu Y, Gutterman DD. Vascular control in humans: focus on the coronary microcirculation. Basic Res Cardiol. 2009;104:211–27.PubMedCrossRef

31.

Knaapen P, Camici PG, Marques KM, Nijveldt R, Bax JJ, Westerhof N, et al. Coronary microvascular resistance: methods for its quantification in humans. Basic Res Cardiol. 2009;104:485–98.

32.

Heusch G. Adenosine and maximum coronary vasodilation in humans: myth and misconceptions in the assessment of coronary reserve. Basic Res Cardiol. 2010;105:1–5.PubMedCrossRef

33.

Beyer AM, Gutterman DD. Regulation of the human coronary microcirculation. J Mol Cell Cardiol. 2011;52:814–21.PubMedCrossRef

34.

Zhang C. The role of inflammatory cytokines in endothelial dysfunction. Basic Res Cardiol. 2008;103:398–406.PubMedCrossRef

35.

Li J, Zhang H, Zhang C. Role of inflammation in the regulation of coronary blood flow in ischemia and reperfusion: mechanisms and therapeutic implications. J Mol Cell Cardiol. 2011;52:865–72.PubMedCrossRef

36.

Heusch G. a-Adrenergic mechanisms in myocardial ischemia. Circulation. 1990;81:1–13.PubMedCrossRef

37.

Heusch G, Baumgart D, Camici P, Chilian W, Gregorini L, Hess O, et al. a-Adrenergic coronary vasoconstriction and myocardial ischemia in humans. Circulation. 2000;101:689–94.

38.

Heusch G. The paradox of a-adrenergic coronary vasoconstriction revisited. J Mol Cell Cardiol. 2011;51:16–23.PubMedCrossRef

39.

Gregorini L, Marco J, Heusch G. Peri-interventional coronary vasomotion. J Mol Cell Cardiol. 2011;52:883–9.PubMedCrossRef

40.

Puri R, Liew GY, Nicholls SJ, Nelson AJ, Leong DP, Carbone A, et al. Coronary β₂-adrenoreceptors mediate endothelium-dependent vasoreactivity in humans: novel insights from an in vivo intravascular ultrasound study. Eur Heart J. 2012;33:495–504.

41.

Duncker DJ, Bache RJ. Regulation of coronary vasomotor tone under normal conditions and during acute myocardial hypoperfusion. Pharmacol Ther. 2000;86:87–110.PubMedCrossRef

42.

Heusch G, Yoshimoto N, Müller-Ruchholtz ER. Effects of heart rate on hemodynamic severity of coronary artery stenosis in the dog. Basic Res Cardiol. 1982;77:562–73.PubMedCrossRef

43.

Heusch G, Yoshimoto N. Effects of heart rate and perfusion pressure on segmental coronary resistances and collateral perfusion. Pflügers Arch. 1983;397:284–9.PubMedCrossRef

44.

Heusch G, Yoshimoto N. Effects of cardiac contraction on segmental coronary resistances and collateral perfusion. Int J Microcirc. 1983;2:131–41.

45.

Raff WK, Kosche F, Lochner W. Extravascular coronary resistance and its relation to microcirculation. Am J Cardiol. 1972;29:598–603.PubMedCrossRef

46.

Hoffman JIE. Determinants and prediction of transmural myocardial perfusion. Circulation. 1978;58:381–91.PubMedCrossRef

47.

Gorman MW, Sparks HV Jr. Progressive coronary vasoconstriction during relative ischemia in canine myocardium. Circ Res. 1982;51:411–20.PubMedCrossRef

48.

Aversano T, Becker LC. Persistence of coronary vasodilator reserve despite functionally significant flow reduction. Am J Physiol. 1985;248:H403–11.PubMed

49.

Canty JM, Klocke FJ. Reduced regional myocardial perfusion in the presence of pharmacologic vasodilator reserve. Circulation. 1985;71:370–7.PubMedCrossRef

50.

Heusch G, Guth BD, Seitelberger R, Ross Jr. J. Attenuation of exercise-induced myocardial ischemia in dogs with recruitment of coronary vasodilator reserve by nifedipine. Circulation. 1987;75:482–90.

51.

Guth BD, Schulz R, Heusch G. Time course and mechanisms of contractile dysfunction during acute myocardial ischemia. Circulation. 1993;87(Suppl IV):IV-35–42

52.

Heusch G, Deussen A, Thämer V. Cardiac sympathetic nerve activity and progressive vasoconstriction distal to coronary stenoses: feed-back aggravation of myocardial ischemia. J Auton Nerv Syst. 1985;13:311–26.PubMedCrossRef

53.

Heusch G, Deussen A. The effects of cardiac sympathetic nerve stimulation on the perfusion of stenotic coronary arteries in the dog. Circ Res. 1983;53:8–15.PubMedCrossRef

54.

Seitelberger R, Guth BD, Heusch G, Lee JD, Katayama K, Ross Jr. J. Intracoronary a₂- adrenergic receptor blockade attenuates ischemia in conscious dogs during exercise. Circ Res. 1988;62:436–42.

55.

Kröger K, Schipke J, Thämer V, Heusch G. Poststenotic ischemic myocardial dysfunction induced by peripheral nociceptive stimulation. Eur Heart J. 1989;10(Suppl F):179–82.PubMed

56.

Baumgart D, Haude M, Goerge G, Liu F, Ge J, Große-Eggebrecht C, et al. Augmented α-adrenergic constriction of atherosclerotic human coronary arteries. Circulation. 1999;99:2090–7.

57.

Baumgart D, Naber C, Haude M, Oldenburg O, Erbel R, Heusch G, et al. G-protein b3 subunit 825T-allele and enhanced coronary vasoconstriction upon a₂-adrenoceptor activation. Circ Res. 1999;85:965–9.

58.

Heusch G. Emerging importance of alpha-adrenergic coronary vasoconstriction in acute coronary syndromes and its genetic background. J Am Coll Cardiol. 2003;41:195–6.PubMedCrossRef

59.

Gregorini L, Marco J, Kozàkovà M, Palombo C, Anguissola GB, Marco I, et al. a-Adrenergic blockade improves recovery of myocardial perfusion and function after coronary stenting in patients with acute myocardial infarction. Circulation. 1999;99:482–90.

60.

Gregorini L, Marco J, Farah B, Bernies M, Palombo C, Kozakova M, et al. Effects of selective a₁- and a₂-adrenergic blockade on coronary flow reserve after coronary stenting. Circulation. 2002;106:2901–7.

61.

Ertl G. Coronary vasoconstriction in experimental myocardial ischemia. J Cardiovasc Pharmacol. 1987;9(Suppl 2):S9–17.PubMedCrossRef

62.

Saino A, Pomidossi G, Perondi R, Valentini R, Rimini A, Di Francesco L, et al. Intracoronary angiotensin II potentiates coronary sympathetic vasoconstriction in humans. Circulation. 1997;96:148–53.

63.

Hasdai D, Kornowski R, Battler A. Endothelin and myocardial ischemia. Cardiovasc Drugs Ther. 1994;8:589–99.PubMedCrossRef

64.

Hirsh PD, Hillis LD, Campbell WB, Firth BG, Willerson JT. Release of prostaglandins and thromboxane into the coronary circulation in patients with ischemic heart disease. N Engl J Med. 1981;304:685–91.

65.

van den Berg EK, Schmitz JM, Benedict CR, Malloy CR, Willerson JT, Dehmer GJ. Transcardiac serotonin concentration is increased in selected patients with limiting angina and complex coronary lesion morphology. Circulation. 1989;79:116–24.

66.

Erbel R, Heusch G. Brief review: coronary microembolization. J Am Coll Cardiol. 2000;36:22–4.PubMedCrossRef

67.

Heusch G, Kleinbongard P, Böse D, Levkau B, Haude M, Schulz R, et al. Coronary microembolization: from bedside to bench and back to bedside. Circulation. 2009;120:1822–36.

68.

Kleinbongard P, Konorza T, Böse D, Baars T, Haude M, Erbel R, et al. Lessons from human coronary aspirate. J Mol Cell Cardiol. 2011;52:890–6.

69.

Böse D, Leineweber K, Konorza T, Zahn A, Brocker-Preuss M, Mann K, et al. Release of TNF-a during stent implantation into saphenous vein aortocoronary bypass grafts and its relation to plaque extrusion and restenosis. Am J Physiol Heart Circ Physiol. 2007;292:H2295–9.

70.

Kleinbongard P, Böse D, Baars T, Möhlenkamp S, Konorza T, Schöner S, et al. Vasoconstrictor potential of coronary aspirate from patients undergoing stenting of saphenous vein aortocoronary bypass grafts and its pharmacological attenuation. Circ Res. 2010;108:344–52.

71.

Leineweber K, Böse D, Vogelsang M, Haude M, Erbel R, Heusch G. Intense vasoconstriction in response to aspirate from stented saphenous vein aortocoronary bypass grafts. J Am Coll Cardiol. 2006;47:981–6.

72.

Kleinbongard P, Böse D, Konorza T, Steinhilber F, Möhlenkamp S, Eggebrecht H, et al. Acute vasomotor paralysis and potential downstream effects of paclitaxel from stents implanted for saphenous vein aorto-coronary bypass stenosis. Basic Res Cardiol. 2011;106:681–9.

73.

Rubanyl GM, Frye RL, Holmes DR, et al. Vasoconstrictor activity of coronary sinus plasma from patients with coronary artery disease. J Am Coll Cardiol. 1987;9:1243–9.PubMedCrossRef

74.

Golino P, Piscione F, Benedict CR, Anderson HV, Cappelli-Bigazzi M, Indolfi C, et al. Local effect of serotonin released during coronary angioplasty. N Engl J Med. 1994;330:523–8.

75.

Leosco D, Fineschi M, Pierli C, Fiaschi A, Ferrara N, Bianco S, et al. Intracoronary serotonin release after high-pressure coronary stenting. Am J Cardiol. 1999;84:1317–22.

76.

Niccoli G, Lanza GA, Shaw S, Romagnoli E, Gioia D, Burzotta F, et al. Endothelin-1 and acute myocardial infarction: a no-reflow mediator after successful percutaneous myocardial revascularization. Eur Heart J. 2006;27:1793–8.

77.

Adlbrecht C, Bonderman D, Plass C, Jakowitsch J, Beran G, Sperker W, et al. Active endothelin is an important vasoconstrictor in acute coronary thrombi. Thromb Haemost. 2007;97:642–9.

78.

Bonderman D, Teml A, Jakowitsch J, Adlbrecht C, Gyöngyösi M, Sperker W, et al. Coronary no-reflow is caused by shedding of active tissue factor from dissected atherosclerotic plaque. Blood. 2002;99:2794–800.

79.

Brambilla M, Camera M, Colnago D, Marenzi G, De MM, Giesen PL, et al. Tissue factor in patients with acute coronary syndromes: expression in platelets, leukocytes, and platelet-leukocyte aggregates. Arterioscler Thromb Vasc Biol. 2008;28:947–53.

80.

Mishra SK, Hermsmeyer K. Inhibition of signal Ca²⁺ in dog coronary arterial vascular muscle cells by Ro 40–5967. J Cardiovasc Pharmacol. 1994;24:1–7.PubMedCrossRef

81.

Boström S-L, Ljung B, Mardh S, Forsen S, Thulin E. Interaction of the antihypertensive drug felodipine with calmodulin. Nature. 1981;292:777–8.

82.

Ehring T, Heusch G. Calciumantagonisten bei experimenteller Myokardischämie und Reperfusion. In: Kübler W, Tritthart HA, editors. Calciumantagonisten. Forschung und Klinik, Vergangenheit, Gegenwart und Zukunft. Darmstadt: Steinkopff; 1996. pp. 57–119.

83.

Vatner SF, Hintze TH. Effects of a calcium- channel antagonist on large and small coronary arteries in conscious dogs. Circulation. 1982;66:579–88.PubMedCrossRef

84.

Heusch G, Deussen A, Schipke J, Thä V. a₁- and a₂-Adrenoceptor-mediated vasoconstriction of large and small canine coronary arteries in vivo. J Cardiovasc Pharmacol. 1984;6:961–8.PubMedCrossRef

85.

Heusch G, Deussen A. Nifedipine prevents sympathetic vasoconstriction distal to severe coronary stenoses. J Cardiovasc Pharmacol. 1984;6:378–83.PubMedCrossRef

86.

Ehring T, Heusch G. Felodipine prevents the poststenotic myocardial ischemia induced by a₂-adrenergic coronary constriction. Cardiovasc Drugs Ther. 1990;4:443–9.PubMedCrossRef

87.

Heusch G, Deussen A, Schipke J, Thä V. Adenosine, dipyridamole and isosorbiddinitrate are ineffective to prevent the sympathetic initiation of poststenotic myocardial ischemia. Drug Res. 1986;36:1045–8.

88.

Nissen SE, Tuzcu EM, Libby P, Thompson PD, Ghali M, Garza D, et al. Effect of antihypertensive agents on cardiovascular events in patients with coronary disease and normal blood pressure. The CAMELOT study: a randomized controlled trial. JAMA. 2004;292:2217–26.

89.

Poole-Wilson PA, Lubsen J, Kirwan BA, van Dalen FJ, Wagener G, Danchin N, et al. Effect of long-acting nifedipine on mortality and cardiovascular morbidity in patients with stable angina requiring treatment (ACTION trial): randomised controlled trial. Lancet. 2004;364:849–57.

90.

Fox K, Garcia MA, Ardissino D, Buszman P, Camici PG, Crea F, et al. Guidelines on the management of stable angina pectoris: executive summary: the task force on the management of stable angina pectoris of the European Society of Cardiology. Eur Heart J. 2006;27:1341–81.

91.

Deedwania PC, Carbajal EV. Medical therapy versus myocardial revascularization in chronic coronary syndrome and stable angina. Am J Med. 2011;124:681–8.PubMedCrossRef

92.

Deedwania PC, Carbajal EV, Bobba VR. Trials and tribulations associated with angina and traditional therapeutic approaches. Clin Cardiol. 2007;30:I16–24.PubMedCrossRef

93.

Furberg CD, Psaty BM, Meyer JV. Nifedipine. Dose-related increase in mortality in patients with coronary heart disease. Circulation. 1995;92:1326–31.PubMedCrossRef

94.

Opie LH, Yusuf S, Kubler W. Current status of safety and efficacy of calcium channel blockers in cardiovascular diseases: a critical analysis based on 100 studies. Prog Cardiovasc Dis. 2000;43:171–96.PubMedCrossRef

95.

Chaitman BR, Laddu AA. Stable angina pectoris: antianginal therapies and future directions. Nat Rev Cardiol. 2012;9:40–52.CrossRef

96.

Schwartz BG, Kloner RA. Coronary no reflow. J Mol Cell Cardiol. 2011;52:873–82.PubMedCrossRef

97.

van de Werf F, Bax J, Betriu A, Blomstrom-Lundqvist C, Crea F, Falk V, et al. Management of acute myocardial infarction in patients presenting with persistent ST-segment elevation: the task force on the management of ST-segment elevation acute myocardial infarction of the European Society of Cardiology. Eur Heart J. 2008;29:2909–45.

98.

Wijns W, Kolh P, Danchin N, Di Mario C, Falk V, Folliguet T, et al. Guidelines on myocardial revascularization: the task force on myocardial revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J. 2010;31:2501–55.

99.

Desmet W, Bogaert J, Dubois C, Sinnaeve P, Adriaenssens T, Pappas C, et al. High-dose intracoronary adenosine for myocardial salvage in patients with acute ST-segment elevation myocardial infarction. Eur Heart J. 2011;32:867–77.

100.

Heyndrickx GR, Millard RW, McRitchie RJ, Maroko PR, Vatner SF. Regional myocardial functional and electrophysiological alterations after brief coronary artery occlusion in conscious dogs. J Clin Invest. 1975;56:978–85.

101.

Heyndrickx GR, Baig H, Nellens P, Leusen I, Fishbein MC, Vatner SF. Depression of regional blood flow and wall thickening after brief coronary occlusions. Am J Physiol Heart Circ Physiol. 1978;234:H653–9.

102.

Braunwald E, Kloner RA. The stunned myocardium: prolonged, postischemic ventricular dysfunction. Circulation. 1982;66:1146–9.PubMedCrossRef

103.

Bolli R. Mechanism of myocardial “stunning”. Circulation. 1990;82:723–38.PubMedCrossRef

104.

Bolli R. Myocardial “stunning” in man. Circulation. 1992;86:1671–91.PubMedCrossRef

105.

Heusch G. Stunning—great paradigmatic, but little clinical importance. Basic Res Cardiol. 1998;93:164–6.PubMedCrossRef

106.

Heusch G, Rose J, Skyschally A, Post H, Schulz R. Calcium responsiveness in regional myocardial short-term hibernation and stunning in the in situ porcine heart—inotropic responses to postextrasystolic potentiation and intracoronary calcium. Circulation. 1996;93:1556–66.

107.

Heusch G. Therapy of myocardial stunning. Basic Res Cardiol. 1997;92(Suppl 2):30–1.PubMed

108.

Ehring T, Heusch G. Stunned myocardium and the attenuation of stunning by calcium antagonists. Am J Cardiol. 1995;75:61E–7.PubMedCrossRef

109.

Sheiban I, Tonni S, Benussi P, Marini A, Montresor G, Trevi GP. Myocardial stunning following coronary angioplasty: protective effects of calcium-channel blockers. J Cardiovasc Pharmacol. 1992;20(Suppl 5):S18–24.

110.

Heusch G. Myocardial stunning: a role for calcium antagonists during ischaemia? Cardiovasc Res. 1992;26:14–9.PubMedCrossRef

111.

Ehring T, Böhm M, Heusch G. The calcium antagonist nisoldipine improves the functional recovery of reperfused myocardium only when given before ischemia. J Cardiovasc Pharmacol. 1992;20:63–74.PubMed

112.

Rose J, Heusch G. Attenuation of regional myocardial stunning by felodipine. Cardiovasc Drugs Ther. 1996;10:347–9.PubMed

113.

Przyklenk K, Ghafari GB, Eitzman DT, Kloner RA. Nifedipine administered after reperfusion ablates systolic contractile dysfunction of postischemic “stunned” myocardium. J Am Coll Cardiol. 1989;13:1176–83.PubMedCrossRef

114.

Burns RJ, Gibbons RJ, Yi Q, Roberts RS, Miller TD, Schaer GL, et al. The relationships of left ventricular ejection fraction, end-systolic volume index and infarct size to six-month mortality after hospital discharge following myocardial infarction treated by thrombolysis. J Am Coll Cardiol. 2002;39:30–6.

115.

Wu E, Ortiz JT, Tejedor P, Lee DC, Bucciarelli-Ducci C, Kansal P, et al. Infarct size by contrast enhanced cardiac magnetic resonance is a stronger predictor of outcomes than left ventricular ejection fraction or end-systolic volume index: prospective cohort study. Heart. 2008;94:730–6.

116.

Skyschally A, Schulz R, Heusch G. Pathophysiology of myocardial infarction: protection by ischemic pre- and postconditioning. Herz. 2008;33:88–100.PubMedCrossRef

117.

Schulz R, Post H, Jalowy A, Backenköhler U, Dörge H, Vahlhaus C, et al. Unique cardioprotective action of the new calcium antagonist mibefradil. Circulation. 1999;99:305–11.

118.

Wallbridge DR, Schulz R, Braun C, et al. No attenuation of ischaemic preconditioning by the calcium antagonist nisoldipine. J Mol Cell Cardiol. 1996;28:1801–10.PubMedCrossRef

119.

Hansen JF. Calcium antagonists and myocardial infarction. Cardiovasc Drugs Ther. 1991;5:665–70.PubMedCrossRef

120.

Baumgart D, Ehring T, Krajcar M, Heusch G. A proischemic action of nisoldipine: relationship to a decrease in perfusion pressure and comparison to dipyridamole. Cardiovasc Res. 1993;27:1254–9.PubMedCrossRef

121.

Behrends M, Schulz R, Heusch G. Effects of verapamil and mibefradil on regional blood flow and function in normal and ischemic myocardium. Cardiovasc Drugs Ther. 1999;13:275–6.PubMedCrossRef

122.

Opie LH. Should calcium antagonists be used after myocardial infarction? Ischemia selectivity versus vascular selectivity. Cardiovasc Drugs Ther. 1992;6:19–24.PubMedCrossRef

123.

Heusch G. Ischemia-selectivity: a new concept of cardioprotection by calcium antagonists. Basic Res Cardiol. 1994;89:2–5.PubMedCrossRef

124.

Grossman E, Messerli FH. Effect of calcium antagonists on sympathetic activity. Eur Heart J. 1998;19(Suppl F):F27–31.PubMed

Titel: Calcium antagonists in myocardial ischemia/reperfusion—update 2012
verfasst von: Petra Kleinbongard, PhD
Theodor Baars, MD
Prof. Dr. med. Dr. h.c. Gerd Heusch, FRCP
Publikationsdatum: 01.07.2012
Verlag: Springer Vienna
Erschienen in: Wiener Medizinische Wochenschrift / Ausgabe 13-14/2012
Print ISSN: 0043-5341
Elektronische ISSN: 1563-258X
DOI: https://doi.org/10.1007/s10354-012-0113-0

Springer Medizin Österreich

Summary

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 13-14/2012

The physiology of cardiac calcium handling

Calcium handling and atrial fibrillation

Odontogene Infektionen – Teil I

Calcium handling and ventricular tachyarrhythmias

Pharmacology of myocardial calcium-handling

Arrhythmia-associated cardiac Ca2+ cycling proteins and gene mutations